Finalized May 2020

Overview of Inflammatory Bowel Diseases (IBD) for Healthcare Professionals

ORIGINAL AUTHORS:

LISA B. MALTER, M.D., FACG, AGAF
ASSOCIATE PROFESSOR OF MEDICINE
NYU SCHOOL OF MEDICINE
DIRECTOR, IBD PROGRAM
BELLEVUE HOSPITAL
DIRECTOR OF EDUCATION, IBD CENTER
NYU LANGONE HEALTH

JILL GAIDOS, M.D., FACG
ASSOCIATE PROFESSOR OF MEDICINE
DIRECTOR OF CLINICAL RESEARCH, YALE IBD PROGRAM
VICE CHIEF OF CLINICAL RESEARCH
SECTION OF DIGESTIVE DISEASES
YALE UNIVERSITY

REVIEWED BY THE CROHN'S & COLITIS FOUNDATION'S

PROFESSIONAL EDUCATION COMMITTEE

CROHN'S & COLITIS FOUNDATION

Last modified May 2020

Purpose & Intended Audience

This deck was created to provide a succinct overview of IBD for an audience of healthcare professionals working with adult IBD patients and is estimated to be a one-hour presentation. Suggested speaker notes are included. You may pick and choose the slides that are most useful for your presentation.

Suggested Objectives

1. Recognize the impact of IBD
2. Recognize the causes of IBD
3. Describe the clinical features and symptoms of IBD
4. Identify the techniques used to diagnose IBD
5. Develop a treatment plan based on disease activity and severity
6. List treatment options for mild, moderate, and severe IBD
7. Discuss the importance of a coordinated care team in the care of an IBD patient
8. Discuss additional considerations in the care of IBD patients including shared decision-making, special populations, and insurance

Disclaimer

This deck was created with the intent of providing the most up-to-date information as of May 2020. However, it is the responsibility of the presenter to review and update the information as needed to ensure accuracy. The Foundation shall not be liable for any added/modified language utilized by presenter. Any added or modified content will be clearly labeled as such and presenter will own the copyright solely to the added content.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Overview of IBD

- Definition
- Incidence
- Pathogenesis
- Cost

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

What Is Inflammatory Bowel Diseases?

- IBD is characterized by:
  - Chronic, immune-mediated inflammation in the gastrointestinal (GI) tract
  - Often has a progressive, destructive course
- The two major forms of IBD are Crohn's disease (CD) and ulcerative colitis (UC)
- **IBD is *not* IBS (irritable bowel syndrome)**
- Incidence of IBD has significantly increased over time in the U.S.
- An estimated 1.6-3.1 million are living with Crohn's or ulcerative colitis in the U.S.

1. CDC. http://www.cdc.gov/ibd/#epidIBD. Accessed April 13, 2017.
2. Kornbluth A, et al. *Am J Gastroenterol*. 2010;105(3):501-523.
3. Lichtenstein GR, et al. *Am J Gastroenterol.* 2009;104(2):465-483.
4. Crohn's & Colitis Foundation. (2014). *The Facts about Inflammatory Bowel Disease* [Fact Book].
5. Loftus CG, et al. *Inflamm Bowel Dis.* 2007;13(3):254-261.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Pathogenesis of IBD



Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Economic Impact of IBD in the United States



Trends in all-cause costs in IBD



Cost ratios of IBD pharmacotherapy

Adapted from: Park KT et al. *Inflamm Bowel Dis* 2019; 26(1): 1-10

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Diagnosis of IBD

- Goals
- Differential Diagnosis
- Algorithm
- Clinical Features
- Symptoms
- Colonoscopy & Endoscopy
- Pathology
- Extraintestinal Manifestations

Last modified May 2020

Diagnosis of IBD

- Diagnostic goals should include:
  - Determining if CD vs. UC
    - Up to 10% are diagnosed as indeterminate colitis
  - Mapping the extent of disease burden
  - Identifying disease behavior (specifically for CD)
  - Recognizing severity
- There is no “gold standard” test for diagnosing IBD
- Must utilize history, exam findings, family history and diagnostic testing

Differential Diagnosis When Considering IBD

- Infectious colitis (including *Clostridiodes difficile*)
- Ischemic colitis
- Drug-induced (NSAID) enterocolitis
- Solitary rectal ulcer syndrome
- Radiation enterocolitis
- Sexually transmited infections
- Diversion colitis
- Endometriosis
- Malignancy
- Functional disorder (especially irritable bowel syndrome)
- Diverticular disease

Learn more about the most common conditions misdiagnosed as IBD at: www.crohnscolitisfoundation.org/clinical-pearls

Adapted from: Forcione DG, Sands BE. In: Sartor RB, Sandborn WJ. *Kirsner's Inflammatory Bowel Diseases.* 6th ed. New York, NY: Saunders; 2004:359-379.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Proposed IBD Diagnostic Algorithm for First Presentation



*Consider if inflammatory markers are elevated, if iron deficiency is present or if there is elevated fecal calprotectin with negative prior diagnostic workup. Use with caution in patients with potential strictures.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Clinical Features of UC and CD

Ulcerative Colitis	Crohn's Disease
Colon and rectum	Any part of the GI tract
Rectum universally involved	Rectum involved in 10% of cases
Mucosal and submucosal injury	Transmural injury that may lead to strictures or fistulae including perianal involvement
Continuous pattern of inflammation	Skip lesions
Acute onset	Insidious onset

~10% do not fit into either group and are deemed indeterminate colitis

Predominant Symptoms of UC

- Rectal bleeding
- Frequent, small volume, loose stools
- Mucous discharge from the rectum
- Tenesmus, urgency, rectal pain
- Abdominal pain



Basson MD. Ulcerative colitis. http://emedicine.medscape.com/article/183084-overview. Updated February 14, 2017.

Last modified May 2020

Ulcerative Colitis: Colonoscopy and Biopsy



Diffuse, prominent crypt architectural distortion and mucosal atrophy, with foci of crypt dropout. No granulomas.

Images courtesy of David T. Rubin, MD

Endoscopic Severity of UC Using Mayo Score

Mayo Endoscopic Subscore	
Mucosal appearance at endoscopy	
Normal or inactive disease	0
Mild disease (erythema, decrease vascular pattern, mild friability)	1
Moderate disease (marked erythema, absent vascular pattern, friability, erosions)	2
Severe disease (spontaneous bleeding, ulceration)	3

Adapted from Lemmens et al. *Inflamm Bowel Dis.* 2013; 19(6): 1194-1201.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Natural History of Crohn's Disease



Pariente B et al. *Inflamm Bowel Dis* 2011;17(6):1415-1422.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Clinical Features of CD: Depend on Location & Phenotype

1. **Inflammatory**
<u>Small bowel</u>:
abdominal pain, diarrhea, fever
<u>Colonic:</u>
diarrhea +/- hematochezia, weight loss, fever

2. **Stricturing**
Bowel obstructions

3. **Penetrating**
Abscesses, fistulae



Farmer RG, et.al. *Dig Dis Sci*. 1993;38(6):1137-1146.

Feuerstein D et. al. Mayo Clin Proc. 2017; 92(7):1088-1103

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Endoscopy in CD



Normal Colon



Deep Ulceration



Ulcerations in the Ileum

Endoscopic Severity of CD: Simple Endoscopic Score (SES-CD)

Variables	0	1	2	3
Size of ulcers, cm	None	0.1-0.5	0.5-2	>2
Ulcerated surface, %	None	<10	10-30	>30
Affected surface, %	Unaffected segment	<50	50-75	>75
Presence of stenosis	None	Single, can be passed	Multiple, can be passed	Cannot be passed

Adapted from Takenaka et al. *Inflamm Bowel Dis.* 2015; 21(8): 1832–1838.

Capsule Endoscopy in Crohn's Disease



FIGURE 6. A,B, CE positive for SB mucosal disease. The arrow points to small bowel mucosal disease found on capsule endoscopy

Adapted from Hansel L et al. *Inflamm Bowel Dis;* 2018; 24(7): 1582-1588.

CROHN'S & COLITIS FOUNDATION

Pathology of CD: Transmural Inflammation & Granulomata





Images courtesy of Dr. Robert Lippman, McGuire VA Medical Center, Richmond, Virginia

Extraintestinal Manifestations of IBD



Figure 1. A, Oral aphthous ulcers, (B) Sweet's syndrome, (C) erythema nodosum, (D) pyoderma gangrenosum, (E) peristomal pyoderma gangrenosum, (F) episcleritis, (G) uveitis with hypopyon and dilated iris vessels, (H) conventional x-ray of the lateral spine demonstrating syndesmophytes (bamboo spine), (I) plane radiograph of the ileosacral joints with bilateral sacroiliitis, (J) plane radiography of the sacrum with bilateral ankylosis, (K) coronal magnetic resonance image of the sacroiliac joints with active inflammation mainly on the left side and chronic inflammatory changes on both sides.

Adapted from: Vavricka R. et al *Inflamm Bowel Dis.* 2015; 21(8): 1982-1992

Last modified May 2020

Treatment of IBD

- Approach & Goals
- Medication Options for Mild, Moderate, & Severe IBD
- Adverse Effects
- Loss of Response

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Treatment of IBD

- Need to determine appropriate treatment based on:
  - IBD-related characteristics:
    - Disease activity
    - Disease severity
    - Complications of IBD
    - Response to prior IBD treatment(s)
  - Non-IBD characteristics:
    - Current infection
    - Comorbidities

Modified from AGA Institute Guidelines for the Identification, Assessment and Initial Medical Treatment in Crohn's Disease Clinical Decision Support Tool available at: https://s3.amazonaws.com/agaassets/pdf/guidelines/IBDCarePathway.pdf

Determining Disease Activity and Severity

- Disease ***activity*** is based on:
  - Patient-reported outcomes (PROs)
    - Using disease activity scores, i.e. Harvey-Bradshaw Activity Index (CD), Modified Mayo Score or the Simple Clinical Colitis Activity Score for UC
  - Inflammatory burden
    - Based on extent of disease and severity of endoscopic findings and/or other non-invasive markers of inflammation, such as fecal calprotectin, ESR or CRP
- Disease ***severity*** is based on:
  - Risk factors for more severe disease prognosis

Siegel CA, Whitman CB, Spiegel BMR, *et al* Development of an index to define overall disease severity in IBD. Gut 2018;67:244-254.

Disease Activity for UC Using Simple Clinical Colitis Activity Index

SCCAI Remission < 2.5
Bowel frequency (day)
0 = 1–3
1 = 4–6
2 = 7–9
3 = >9
Bowel frequency (night)
1 = 1–3
2 = 4–6
Urgency of defecation
1 = hurry
2 = immediately
3 = incontinence
Blood in stool
1 = trace
2 = occasionally frank
3 = usually frank
General well-being
0 = very well
1 = slightly below par
2 = poor
3 = very poor
4 = terrible
Arthritis, pyoderma gangrenosum, erythema nodosum, uveitis
1 per manifestation

Extracolonic features include arthralgia, uveitis, rash, oral ulcers.

Score of < 4 is inactive disease.

Adapted from: Bewtra et al *Inflamm Bowel Dis.* 2015; 20(6): 1070-1078.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Disease Activity for CD Using Harvey Bradshaw Activity Index

- Score* based on parameters of:
  - 1)Well-being of the patient (Score 0-4)
  - 2)Abdominal pain (Score 0-3)
  - 3)Number of liquid or soft stools (Score of 1 for each liquid bowel movement)
  - 4)Abdominal mass (Score 0-3)
  - 5) Complications (Score 1 per complication)

*Total score determines inactive disease (<5), mild disease (5-7), moderate disease (8-16), or severe disease (>16)

Can be found at: https://www.igibdscores.it/en/info-hbi.html

Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 315 (8167): 514; IGIBD Scores https://www.igibdscores.it/en/info-hbi.html

Last modified May 2020

Risk Factors for Having Severe or Complicated IBD

Ulcerative Colitis	Crohn's Disease
Age < 40 at diagnosis	Age < 30 at diagnosis
Extensive colonic involvement	Extensive anatomic involvement
Severe endoscopic disease activity (i.e. Mayo score ≥3, UCEIS ≥7)	Perianal and/or severe rectal disease
Requiring hospitalization for colitis	Deep ulcers
Elevated C-reactive protein	Prior surgical resection
Low serum albumin	Stricturing and/or penetrating behavior

1. Modified from Rubin DT et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastro 2019;114:384-419
2. Modified from AGA Institute Guidelines for the Identification, Assessment and Initial Medical Treatment in Crohn's Disease Clinical Decision Support Tool available at: https://s3.amazonaws.com/agaassets/pdf/guidelines/IBDCarePathway.pdf; *Gastroenterology* 2014 147702-705DOI: (10.1053/j.gastro.2014.07.022) Copyright © 2014

Last modified May 2020

Goals of Treatment for IBD Patients



- Clinical remission (i.e. IBD symptoms have resolved)
- Mucosal improvement (i.e. overall decrease in mucosal inflammation)
- On a steroid-free treatment regimen

The medication that works best is the one your patient will take consistently.

CROHN'S & COLITIS FOUNDATION

Why Is Mucosal Healing Important?

- In clinical practice, mucosal healing should guide medical therapy
  - Symptoms do not always correlate with mucosal inflammation
  - Need to assess disease activity prior to making medication changes
  - Growing evidence that mucosal healing is an important goal because it appears to be associated with improved long-term outcomes including:
    - Decreased likelihood of a flare
    - Decreased progression to disease complications
    - Decreased need for surgery and hospitalization

Pineton de Chambrun G, et al. *Nat Rev Gastroenterol Hepatol.* 2010;7(1):15-29.

Last modified May 2020

Treatment Options for Mild IBD

Medication	CD/UC	Induction	Maintenance	Administration
Corticosteroids	CD, UC	+	-	Oral, IV, Rectal
Budesonide	CD, UC	+	-	Oral
Aminosalicylates	UC	+	+	Oral, Rectal

Potential Adverse Effects of Treatments for Mild IBD

Medication	Possible Adverse Effects
Corticosteroids	Sleep and mood disturbances, hypertension, glucose intolerance, cataracts, osteoporosis, myopathy, glaucoma, acne, edema, increased risk of infections
Budesonide	Headache, acne, nausea
Aminosalicylates	Nephrotoxicity, interstitial nephritis, nausea, GI disturbance, paradoxical diarrhea

1. Rubin DT et al. *Am J Gastroenterol*. 2019;114(3):384-413.
2. Lichtenstein GR, et al. *Am J Gastroenterol*. 2018;113(4):481-517.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Treatment Options for Moderate – Severe IBD

Medication	CD/UC	Induction	Maintenance	Administration
Thiopurines	CD, UC	-	+	Oral
Methotrexate	CD	-	+	Oral, IM
Anti-TNF Agents	CD, UC	+	+	IV, SC
Vedolizumab	CD, UC	+	+	IV, SC coming soon
Natalizumab	CD	+	+	IV
Ustekinumab	CD, UC	+	+	IV induction, SC maintenance
Tofacitinib	UC	+	+	Oral
Ozanimod	UC	+	+	Oral

Abbreviations: IM=intramuscular; anti-TNF= anti-tumor necrosis factor; IV=intravenous; SC=subcutaneous

1. Rubin DT et al. *Am J Gastroenterol*. 2019;114(3):384-413.
2. Lichtenstein GR, et al. *Am J Gastroenterol*. 2018;113(4):481-517.

Last modified May 2020

Adverse Effects: Treatments for Moderate-Severe IBD

Medication	Possible Adverse Effects
Thiopurines	Bone marrow suppression, hepatotoxicity, pancreatitis, pneumonitis, GI upset, rash, alopecia, fever, arthralgia, lymphoproliferative disorders, myeloid neoplasias, hepatosplenic T-cell lymphoma (young males), non-melanoma skin cancer, hemophagocytic lymphohistiocytosis (after EBV or CMV infection)
Methotrexate	Bone marrow suppression, alopecia, hepatic fibrosis, hypersensitivity pneumonitis, increased risk of infection
Anti-TNF Agents	Increased risk of infection, infusion or injection site reactions, dermatologic and neurologic manifestations, melanoma, lymphoma
Vedolizumab	Upper respiratory tract infections (URI), infusion related reaction
Natalizumab	Headache, rash, nausea, increased risk of infection, infusion related reaction, arthralgia, progressive multifocal leukoencephalopathy (in those with +JC virus antibody)
Ustekinumab	Injection site reaction, cold symptoms, headache, fatigue, increased risk of infection
Tofacitinib	Herpes Zoster, lipid abnormalities, venothromboembolism (specifically pulmonary embolism)
Ozanimod	Increased liver enzymes, bradycardia, hypertension, macular edema, URI, herpes zoster, decreased pulmonary function, headache, fetal risk, posterior reversible encephalopathy syndrome

1. Rubin DT et al. *Am J Gastroenterol*. 2019;114(3):384-413.
2. Lichtenstein GR, et al. *Am J Gastroenterol*. 2018;113(4):481-517.

CROHN'S & COLITIS FOUNDATION

Last modified August 2021

Monitoring for IBD Medications

Medication	Testing Prior to Starting	Recommended Monitoring
Mesalamines	Consider baseline renal function test	Annual renal function monitoring
Corticosteroids		Document plan for long-term therapy, consider ophthalmology exam, DEXA.
Thiopurines	TPMT enzyme activity, CBC and liver function	Routine CBC and liver function while on therapy
Methotrexate	CBC, liver and renal function	Routine CBC, liver and renal function monitoring while on therapy
Anti-TNF Agents	TB screening prior to start, check Hepatitis B panel, CBC and liver function	Assess for TB exposure annually while on therapy; CBC and liver function routinely while on therapy
Vedolizumab	CBC and liver function	CBC and liver function periodically while on therapy
Natalizumab	Enrollment in CD Touch® Prescribing Program	Assess for signs/symptoms suggestive of PML, routine CBC and liver function testing, JC virus antibody testing every 6 months, per CD Touch® Prescribing Program
Ustekinumab	TB screening prior to start, check Hepatitis B panel, CBC and liver function	Assess for TB exposure annually while on therapy; CBC and liver function routinely while on therapy
Tofacitinab	CBC, liver, fasting lipid panel and TB	Assess for TB exposure annually while on therapy, routine CBC and liver function monitoring while on therapy; repeat fasting lipid panel 4-8 weeks after start of therapy.
Ozanimod	CBC with lymphocyte count, liver function, antibodies to varicella, ECG, ophthalmic examination including macula if diabetes or history of uveitis	CBC and liver function periodically while on therapy, routine blood pressure checks; ophthalmic evaluation of the fundus is recommended if any change in vision; spirometric evaluation of respiratory function should be performed if new onset dyspnea.

CROHN'S & COLITIS FOUNDATION

Last modified August 2021

Therapeutic Drug Monitoring for Loss of Response

- Therapeutic drug monitoring (TDM) involves checking serum trough drug and antibody levels of biologic medications to help guide changes in medical therapy.
- There are 2 types of TDM:
  - Reactive TDM
    - When symptoms worsen
    - Improves clinical care and helps to guide changes in management
    - Cost effective
  - Proactive TDM
    - During induction or maintenance, in the absence of clinical symptoms
    - Helpful when considering de-escalating therapy
    - Studies (mainly retrospective) show improved outcomes

Scott FI, et al. *Inflamm Bowel Dis.* 2019;25(Suppl 2):S40–S47.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Surgery as Treatment in IBD

- When to Consider
- Common Procedures
- Postoperative Course

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

When to Consider Surgery in IBD

- Prevalence
  - 10%–20% of patients with UC have surgery
  - Approximately 2/3 of Crohn's patients will need surgery
- Indications for surgery:
  - Dysplasia or cancer
  - Disease unresponsive to medications
    - Due to ongoing active symptoms, persistent fistulas or abscess
  - Intolerable medical side effects
  - Complication of disease
    - Stricture
    - Abscess
    - Fistulae
    - Toxic megacolon
    - Colonic perforation

Maggiori L. et al. Nat Rev Gastroetenterol Hepatol 2013;10:297-306.

Last modified May 2020

The Natural Course of Postoperative CD

Recurrence is clinically silent initially

Histologic	Endoscopic	Radiologic	Clinical	Surgical
				
Within 1 wk	**70%–90% by 1 y**	**Tissue damage**	**30% by 3 y 60% by 5 y**	**50% by 10 y**

Postoperative endoscopic evaluation should take place 6-12 months after surgery to assess for recurrent Crohn's disease with changes in treatment based on the findings.

1. Images courtesy of Miguel Regueiro, MD
2. Nguyen GC et al. Gastroenterology 2017;152:271-275.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Weighing the Risks and Benefits of Treatment



Benefits

- Maintenance of remission
- Improved function and quality of life (QOL)
- Early promotion of mucosal healing to prevent complications and improve long-term outcomes

Disadvantages

- Side effects of medications
- Cost
- Majority of patients may not require more potent treatments initially

1. Lichtenstein GR, et al. *Inflamm Bowel Dis.* 2004;10 (suppl 2):S2-S10.
2. Caprilli R, et al. *Dig Liver Dis.* 2005;37(12):973-979.

Last modified May 2020

Additional Considerations in IBD

- Shared Decision-Making
- Special Populations

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Shared Decision-Making (SDM) in IBD

SDM: A process in which clinicians and patients work together to make decisions and select tests, treatments, and care plans based on clinical evidence that balances risks and expected outcomes with patient preferences and values.

See for further information and tools at:

https://www.crohnscolitisfoundation.org/shared-decisionmaking

The Office of the National Coordinator for Health Information Technology. www.healthIT.gov.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Treating Special Populations with IBD

- During Pregnancy
  - Important for patients to be in remission prior to conception on a treatment regimen that can be safely continued throughout pregnancy
  - Ensure health maintenance is up-to-date prior to conception
  - Pregnancy educational video: https://www.crohnscolitisfoundation.org/science-and-professionals/education-resources/educational-videos-professionals
- Elderly Patients
  - Important to minimize polypharmacy
  - Long-term use of steroids is not appropriate maintenance treatment
- Patients with Prior Malignancy
  - No evidence that any IBD medications increases the risk for solid tumors
  - Discuss risks vs. benefits of treatment

1. Mahadevan U et al. Gastroenterology 2019;156:1508-1424.
2. Ha C et al. Clin Geriatr Med 2014;30:67-78.
3. Loo SY et al. J Crohns Colitis 2019;13:1302-1310.

Last modified May 2020

Comprehensive Care for IBD

- Health Maintenance
- Team Approach
- Insurance

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Health Maintenance Checklist for Adults with IBD



CROHN'S & COLITIS FOUNDATION

Health Maintenance Summary

Vaccines and Infections

Influenza: All patients >6 months of age should receive annual inactivated influenza vaccine, irrespective of immunosuppression status.

MMR: IBD Patients not immune to MMR should receive a 2-dose series, at least 4 weeks apart. If immune status is uncertain, IgG antibody titer should be checked. MMR should not be given to patients currently on systemic immunosuppressive* therapy.

Pneumococcus: All patients >19 years age receiving systemic immunosuppression* should receive PCV13, followed by PPSV23 at least 8 weeks later, and a booster of PPSV23 5 years later.

Varicella: Seroprotection status should be checked with varicella zoster virus IgG antibodies in all patients without documented vaccination record or exposure. All patients who are not immune should receive a 2-dose series, 4–8 weeks apart, ≥4 weeks before immunosuppression, if therapy can be postponed.

Zoster: All patients receiving JAK inhibitor therapy should receive the recombinant adjuvanted zoster vaccine. Risk of zoster should be considered with combinations of other immunosuppressive* therapies.

TB: Screen for latent TB in all patients with IBD, at baseline. Perform clinical risk assessment for TB exposure annually in all patients with IBD.

Cancer Screening

Colorectal Cancer: All IBD patients with extensive colitis (>1/3 of the colon) for ≥ 8 years should undergo surveillance colonoscopy every 1–3 years, depending on cancer risk;

- IBD patients with a diagnosis of PSC should undergo colonoscopy, starting at the time of PSC diagnosis, and annually thereafter.
- IBD patients with features that are high-risk for developing colon cancer (i.e. prior history of adenomatous polyps, dysplasia, family history of colon cancer and extensive colitis) should have colonoscopies more frequently than every 3 years.

Cervical Cancer: All women with IBD who are being treated with systemic immunosuppression* should undergo cervical cancer by cytology annually (if cytology alone) or every 2 years (if HPV negative).

Skin Cancer: All IBD patients being treated with systemic immunosuppression* should have annual total body skin exams to screen for skin cancer.

Other Protection

Osteoporosis: Screen for osteoporosis by central (hip and spine) DXA scan in all patients with IBD if ANY risk factors for osteoporosis; low BMI, >3 months

Depression/Anxiety: Screen all patients with IBD for depression (PHQ9) and anxiety (GAD7) at baseline, and annually. Refer for counseling/therapy when identified.

https://www.crohnscolitisfoundation.org/science-and-professionals/education-resources/health-maintenance-checklists

CROHN'S & COLITIS FOUNDATION

Last modified September 2021

Healthcare team members involved in comprehensive IBD care

• 1^0 Care	→	Health Maintenance
• Pediatricians	→	Transition of Care
• Gastroenterology	→	Coordination of Care
– Dietician/Nutrition	→	Assessment/Management
– Advanced Practitioners	→	F/U, Crisis Management
– Nursing	→	Communications/Support
– MAs/Liaisons	→	Scheduling/Authorizations
– Pharmacy	→	Prescriptions/Infusions
– Social Work	→	Resource utilization
– Behavioral Therapy	→	Self Efficacy
– Clinical Research	→	Clinical Trials

Slide courtesy of Stephen B. Hanauer, MD

Providers Involved in the Care of IBD Patients

- Hospitalist → Inpatient coordination
- Surgeon → Complications
- Pathology → Diagnostics
- Radiology → Diagnostics/Intervention
- Specialists
  - Hepatology → Hepatitis's
  - Ob/Gyne → Contraception/Conception
  - Rheumatology → Joints
  - Endocrine → Bones
  - Ophthalmology → Ocular
  - Nephrology → Stones/Nephropathies
  - Neurology → Peripheral/Central nerves

Slide courtesy of Stephen B. Hanauer, MD

Example Approach: IBD Medical Home



Adapted from: Regueiro MD et al. *Inflamm Bowel Dis* 2016 ; 22 : 1971 – 80.

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Insurance for IBD

- Navigating the insurance process can be challenging:
  - Need prior authorization from companies before being able to switch therapies
  - Effective management may be affected by step therapy, where patients need to fail one class of agents before being able to try another
  - Takes time for approvals
  - Time consuming for both providers & patients

Managing cost of IBD Care webpage:
www.crohnscolitisfoundation.org/managingcosts

- Understanding health insurance
- What to do if denied coverage
- Search for financial assistance programs

Summary

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Key Points

- The incidence and prevalence of IBD in the U.S. are increasing
- The diagnosis of IBD is based on suggestive clinical symptoms, radiographic and/or endoscopic + pathologic findings consistent with Crohn's disease or ulcerative colitis
- The choice of treatment should be based on the disease activity (i.e. patient reported symptoms) and disease severity (i.e. risk factors suggestive of more complicated IBD)
- The goals of treatment are clinical remission (i.e. absence of symptoms) and mucosal improvement (i.e. decreased intestinal inflammation) on a steroid-free treatment regimen
- It is important to discuss the risks and benefits of treatment options with your patient prior to starting therapy to improve compliance
- Lab monitoring prior to starting and throughout treatment as well as ensuring preventive health measures are up-to-date can lower the risk of adverse effects from medication use
- Comprehensive IBD care involves many important healthcare team members

Crohn's & Colitis Foundation Resources

- For Healthcare Providers
- For Patients & Caregivers

Last modified May 2020

CROHN'S & COLITIS FOUNDATION

Crohn's & Colitis Foundation Resources

For Healthcare Providers:

- Online modules on diagnosis, treatment, and surgery
- Fact sheets on nutrition & anemia
- GI Tract Guide
- Educational videos on pregnancy, TDM, biosimilars
- Live training opportunities
- Clinical Pearls
- Online community
- Research Journals
- Dedicated webpage for PAs, NPs, RNs

www.crohnscolitisfoundation.org/prescribereducation

To Share With Your Patients:

- Brochures and fact sheets
- IBD stories
- Treatment options in UC and Crohn's disease
- Mental and emotional well-being
- Diet and nutrition
- Complementary medicine
- Youth and parent resources
- IBD help center
- Camp Oasis
- Financial and insurance information

www.crohnscolitisfoundation.org/

CROHN'S & COLITIS FOUNDATION

Last modified May 2020

Thank You

Last modified May 2020

CROHN'S & COLITIS FOUNDATION